

# F Anthony Romero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1397408/publications.pdf>

Version: 2024-02-01

36  
papers

1,685  
citations

331259

21  
h-index

344852

36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2529  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5031-5073.	2.9	67
2	Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127510.	1.0	8
3	Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. <i>Toxicologic Pathology</i> , 2020, 48, 465-480.	0.9	6
4	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms. <i>Cancer Research</i> , 2019, 79, 3916-3927.	0.4	26
5	Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. <i>Cell Reports</i> , 2019, 27, 269-281.e4.	2.9	37
6	Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1522-1531.	1.0	23
7	Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 39-44.	1.3	35
8	Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 15-23.	1.0	16
9	Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1088-1093.	1.3	4
10	GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9301-9315.	2.9	11
11	Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. <i>Cell Reports</i> , 2018, 24, 1722-1729.	2.9	231
12	GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2). <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 737-741.	1.3	18
13	Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3534-3541.	1.0	28
14	Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1 <i>H</i> -benzo[ <i>c</i> ]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9040-9052.	2.9	21
15	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9162-9183.	2.9	77
16	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5564-5575.	0.4	105
17	A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10151-10171.	2.9	21
18	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5391-5402.	2.9	95

#	ARTICLE	IF	CITATIONS
19	Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. <i>Journal of Biological Chemistry</i> , 2016, 291, 13014-13027.	1.6	58
20	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10549-10563.	2.9	69
21	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 531-536.	1.3	87
22	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1271-1298.	2.9	171
23	The discovery of potent antagonists of NPBWR1 (GPR7). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1014-1018.	1.0	6
24	A one-pot three-component reaction to access 1-alkyl-2-aryl-5-nitrobenzimidazoles under solvent-free conditions. <i>Tetrahedron Letters</i> , 2010, 51, 4459-4461.	0.7	4
25	An efficient method to access 2-substituted benzimidazoles under solvent-free conditions. <i>Tetrahedron Letters</i> , 2008, 49, 1910-1914.	0.7	22
26	Optimization of $\hat{\pm}$ -Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 937-947.	2.9	58
27	Structure-Activity Relationships of $\hat{\pm}$ -Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3359-3368.	2.9	76
28	Potent and Selective $\hat{\pm}$ -Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1058-1068.	2.9	75
29	Delineation of a Fundamental $\hat{\pm}$ -Ketoheterocycle Substituent Effect for Use in the Design of Enzyme Inhibitors. <i>Journal of the American Chemical Society</i> , 2006, 128, 14004-14005.	6.6	50
30	Total Synthesis of Piericidin A1 and B1 and Key Analogues. <i>Journal of the American Chemical Society</i> , 2006, 128, 11799-11807.	6.6	70
31	Exploring the active site of phenylethanolamine N-methyltransferase: 3-alkyl-7-substituted-1,2,3,4-tetrahydroisoquinoline inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 1261-1273.	1.4	9
32	Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoquinolines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1143-1147.	1.0	8
33	Nanomolar Inhibitors of CNS Epinephrine Biosynthesis: $\hat{\Delta}$ (R)-(+)-3-Fluoromethyl-7-(N-substituted) 1,2,3,4-tetrahydroisoquinoline Inhibitors of Phenylethanolamine N-Methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1806-1812.	2.9	15
34	3-Hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline Inhibitors of Phenylethanolamine N-Methyltransferase that Display Remarkable Potency and Selectivity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 134-140.	2.9	17
35	Inhibitors of Phenylethanolamine N-Methyltransferase That Are Predicted To Penetrate the Blood-Brain Barrier: Design, Synthesis, and Evaluation of 3-Fluoromethyl-7-(N-substituted) 1,2,3,4-tetrahydroisoquinoline Inhibitors of $\hat{\pm}$ -Adrenoceptor. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4483-4493.	2.9	23
36	The NH-FC Dipole Orientation Effect for Pendant Exocyclic CH <sub>2</sub> F. <i>Organic Letters</i> , 2002, 4, 3557-3560.	2.4	38